文献速递免疫规划

美国B群脑膜炎球菌疫苗系列完成率与接种时间表依从性:按疫苗类型和支付方分析的回顾性研究

Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type.
PubMed 文献 · Vaccine · 2019-08-20

本研究利用美国商业保险和医疗补助数据库,回顾性分析16-23岁启动MenB疫苗系列者的完成率和接种时间表依从性。结果显示MenB-4C完成率显著高于MenB-FHbp,且完成时间更短,提示MenB-4C的灵活接种方案可能提高依从性。

要点

  • 商业保险人群中MenB-4C完成率63%,MenB-FHbp为52%;医疗补助人群中分别为49%和31%。
  • 接种时间表依从性MenB-4C显著高于MenB-FHbp,商业保险为62% vs 18%,医疗补助为48% vs 8%。
  • 完成系列者中,MenB-4C中位完成时间明显短于MenB-FHbp。

核心结论

  • 研究期间MenB疫苗系列完成率不理想,但MenB-4C完成率显著更高且完成时间更短,可能反映其灵活接种方案的优势。

主要发现

  • 商业保险人群共65,205人(MenB-4C 36,118人,MenB-FHbp 29,087人),医疗补助人群共13,535人(MenB-4C 10,153人,MenB-FHbp 3,382人)。
  • 商业保险中,MenB-4C完成率63%,MenB-FHbp完成率52%;医疗补助中分别为49%和31%。
  • 商业保险中,MenB-4C时间表依从性62%,MenB-FHbp为18%;医疗补助中分别为48%和8%。
  • 完成系列者中位完成时间:商业保险MenB-4C 68天 vs MenB-FHbp 258天;医疗补助MenB-4C 88天 vs MenB-FHbp 309天。

临床怎么用

  • 应关注MenB疫苗系列完成率偏低的问题,尤其针对医疗补助人群和MenB-FHbp接种者,可考虑利用MenB-4C的灵活接种方案提高依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two MenB vaccines with different dosing schedules are approved in the US: MenB-4C (2 doses) and MenB-FHbp (2-3 doses). Both vaccines were licensed on the basis of immunogenicity demonstrated after vaccine series completion. We evaluated vaccination completion and adherence to dosing schedules. METHODS: This retrospective analysis used data from MarketScan Commercial Claims and Encounters Database (Commercial) January 1, 2015 - February 28, 2018 and Multi-State Medicaid Database (Medicaid) January 1, 2015 - December 31, 2017 to examine vaccine series completion and adherence to dosing schedule in individuals who initiated a MenB series at ages 16-23 years. Vaccine series completion and dose schedule adherence were assessed during a 15-month follow-up period after the first dose. Completion was defined as individual receipt of the recommended number of doses, with current recommendations applied retroactively to allow individuals who initiated the MenB-FHbp series to be complete with either the 2- or the 3-dose schedule. RESULTS: The study population comprised 65,205 commercially-insured individuals (36,118 initiated MenB-4C; 29,087 initiated MenB-FHbp) and 13,535 Medicaid-covered individuals (10,153 initiated MenB-4C; 3382 initiated MenB-FHbp). In Commercial, 63% of individuals who initiated MenB-4C and 52% of individuals who initiated MenB-FHbp completed vaccination within 15 months; dosing schedule adherence was 62% for MenB-4C initiators and 18% for MenB-FHbp initiators. In Medicaid, 15-month completion rates for MenB-4C and MenB-FHbp initiators were 49% and 31%, respectively, with corresponding dosing schedule adherence of 48% and 8%. Among individuals who completed the series, median time to completion was 68 days for MenB-4C versus 258 days for MenB-FHbp in Commercial and 88 days for MenB-4C versus 309 days for MenB-FHbp in Medicaid. CONCLUSION: During the study period, MenB vaccine series completion was suboptimal. However, completion was significantly higher for MenB-4C, with notably shorter time to completion. This may reflect the flexible dosing schedule of MenB-4C.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Packnett E, Irwin DE, Novy P, et al. Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type. Vaccine. 2019. PMID: 31443990. doi:10.1016/j.vaccine.2019.06.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。